Critical Concern: Lamotrigine is NOT Indicated for Unipolar Depression or Anxiety
Lamotrigine should not be used for this 16-year-old with anxiety and depression who has failed SSRIs, as it lacks FDA approval and evidence for treating unipolar depression or anxiety disorders in adolescents. The evidence provided addresses lamotrigine only in the context of bipolar disorder, not treatment-resistant unipolar depression 1.
Why Lamotrigine is Inappropriate Here
The available guidelines explicitly state that lamotrigine is approved only for maintenance therapy in bipolar disorder in adults, not for unipolar depression 1. The single adolescent study examined lamotrigine specifically for bipolar depression, not unipolar depression 2. Using lamotrigine for SSRI-resistant unipolar depression in an adolescent represents off-label use without supporting evidence for this population.
Critical Diagnostic Clarification Needed
Before proceeding with any lamotrigine titration, you must definitively establish whether this patient has:
- Bipolar disorder (particularly bipolar II or bipolar depression) that was misdiagnosed as unipolar depression
- True treatment-resistant unipolar depression
The fact that three SSRIs have failed raises the possibility of unrecognized bipolar disorder, especially if there were any signs of activation, mood instability, or treatment-emergent hypomania with the SSRIs 1. The guidelines specifically warn that antidepressants may unmask bipolar disorder or cause disinhibition in youth 1.
If Bipolar Disorder is Confirmed
Only if bipolar disorder is diagnosed should lamotrigine be considered. In that case, use the FDA-approved titration schedule for patients NOT taking enzyme-inducing medications or valproate 3:
Standard Titration Schedule (Immediate-Release Lamotrigine)
- Weeks 1-2: 25 mg once daily
- Weeks 3-4: 50 mg once daily
- Week 5: 100 mg once daily
- Week 6 onward: Increase to target maintenance dose of 200 mg/day (can be given in divided doses or once daily)
Critical Safety Considerations
The primary risk with lamotrigine is Stevens-Johnson syndrome and other serious rashes, which occur in approximately 0.3% of adults and 0.8% of pediatric patients when proper titration is followed 3. Fast titration dramatically increases rash risk (adjusted OR 8.15), while slower titration reduces it (adjusted OR 0.29) 4.
Immediately discontinue lamotrigine if any rash develops, as it is impossible to distinguish benign rashes from potentially life-threatening ones early in their course.
Alternative Approaches for True Unipolar Depression
If this is confirmed unipolar depression, evidence-based alternatives include:
- Switching to a different antidepressant class (SNRIs, bupropion, mirtazapine)
- Augmentation strategies with evidence in adolescents
- Psychotherapy (particularly cognitive-behavioral therapy)
- Reassessment of diagnosis and contributing factors (trauma, substance use, medical conditions)
The one small study showing lamotrigine augmentation with fluoxetine was in adults with mixed bipolar II and unipolar depression, had only 23 patients, and failed to show statistical separation on primary depression rating scales 5.
Bottom Line
Do not initiate lamotrigine for this indication without first confirming bipolar disorder. If bipolar disorder is confirmed, follow the FDA-approved standard titration schedule above, with vigilant monitoring for rash development, particularly in the first 8 weeks of treatment.